thorac
surgeon
occasion
must
involv
diagnosi
treatment
respiratori
tract
infect
addit
complic
postop
pneumonia
surgic
patient
assist
may
need
diagnos
radiograph
abnorm
communityacquir
pneumonia
cap
nosocomi
pneumonia
ventilatorassoci
pneumonia
vap
pneumonia
immunocompromis
host
although
clinic
signific
infect
identifi
respiratori
cultur
microbiolog
analysi
small
percentag
infect
requir
surgic
pathologist
definit
diagnosi
spectrum
burden
etiolog
organ
affect
host
risk
factor
immun
statu
organ
found
less
often
lung
tissu
patient
normal
immun
diagnosi
facilit
cultur
serolog
studi
epidemiolog
data
immunocompromis
host
broader
differenti
must
consid
includ
possibl
multipl
simultan
infect
addit
infect
disord
consid
pulmonari
involv
preexist
diseas
druginduc
treatmentrel
injuri
noninfecti
interstiti
pneumonia
malign
appropri
chest
imag
may
help
narrow
differenti
inform
combin
clinic
histori
time
diseas
acut
subacut
chronic
critic
success
treatment
strategi
articl
review
current
diagnost
modal
medic
treatment
recommend
pulmonari
infect
success
treatment
pulmonari
infect
depend
accur
identif
precipit
pathogen
contemporari
medic
practic
distinct
genu
speci
infecti
organ
import
prognost
therapeut
implic
suspect
pulmonari
infect
defin
sign
symptom
consist
diagnos
pneumonia
clinic
set
consist
acquisit
pneumonia
host
suscept
predispos
pneumonia
exposur
risk
factor
specif
pathogen
pneumonia
sputum
collect
microscop
examin
cultur
expector
mainstay
laboratori
evalu
although
simpl
quick
inexpens
sputum
cultur
nonetheless
neg
growth
time
despit
proven
infect
contamin
oropharynx
secret
also
frequent
issu
sputum
evalu
fail
identifi
caus
factor
definit
identif
requir
success
patient
treatment
invas
sampl
techniqu
avail
includ
bronchoscopi
transthorac
needl
aspir
core
biopsi
surgic
wedg
biopsi
peripher
lung
use
transthorac
approach
specimen
obtain
flexibl
bronchoscop
current
pulmonari
endoscopi
domin
flexibl
bronchoscop
flexibl
provid
advantag
better
access
distal
airway
lavag
wash
aspir
fluid
sampl
suspend
cell
sent
laboratori
millipor
filtrat
cytocentrifugetyp
applic
onto
slide
fig
clinic
guidelin
confirm
valu
bronchoscop
approach
diagnosi
particularli
patient
vap
shown
reduc
mortal
endobronchi
ultrasound
also
ad
avail
diagnost
option
fig
transbronchi
lung
biopsi
peripher
pulmonari
lesion
sampl
mediastin
hilar
lymph
node
may
provid
access
infecti
pathogen
identifi
otherwis
transbronchi
biopsi
techniqu
allow
obtain
sampl
alveolar
lung
parenchyma
beyond
cartilagin
bronchi
endoscop
transbronchi
biopsi
taken
blindli
intend
repres
alveolar
lung
parenchyma
sometim
sampl
bronchial
mucosa
cartilag
branch
point
minor
carina
sampl
directli
fig
mani
type
pulmonari
infect
diagnos
use
fine
needl
aspir
cytolog
evalu
fine
needl
aspir
especi
use
techniqu
respiratori
secret
eg
sputum
bronchial
wash
brush
bronchoalveolar
lavag
often
limit
need
differenti
true
pathogen
contamin
organ
nevertheless
diagnost
tool
complementari
remain
excel
option
diagnosi
local
diffus
pulmonari
infect
electromagnet
navig
bronchoscopi
proven
effect
assess
pulmonari
nodul
accur
low
complic
rate
electromagnet
navig
bronchoscopi
use
comput
guidanc
enabl
bronchoscop
access
pulmonari
lesion
fig
contamin
minim
upper
respiratori
tract
bypass
either
transtrach
transthorac
needl
aspir
presenc
bacteria
becom
much
signific
especi
sheet
neutrophil
andor
necroinflammatori
debri
present
fig
would
case
typic
lobar
lobular
consolid
lung
abscess
complex
pneumonia
fig
context
transthorac
needl
aspir
establish
etiolog
diagnosi
cap
nosocomi
pneumonia
coupl
contemporari
microbiolog
method
current
practic
use
transthorac
needl
aspir
biopsi
becom
commonplac
often
use
target
wellcircumscrib
nodul
infecti
process
must
rule
fig
besid
morpholog
featur
microorgan
import
cytolog
clue
diagnosi
includ
accompani
cellular
respons
presenc
charact
necrot
debri
anaerob
pulmonari
infect
typic
form
lung
abscess
also
approach
way
transthorac
needl
aspir
fig
case
core
biopsi
prefer
aspir
needl
core
biopsi
may
provid
better
abund
diagnost
tissu
wherea
aspir
prefer
evalu
suspect
bacteri
abscess
base
microscop
featur
organ
obtain
techniqu
may
yield
rapid
diagnost
result
addit
respiratori
sampl
pleural
fluid
tap
effus
present
posit
cultur
normal
steril
fluid
circumv
interpret
problem
associ
bacteri
growth
sputum
sampl
persist
effus
suspect
empyema
easili
analyz
thoracentesi
fig
specimen
obtain
thoracoscopi
surgic
biopsi
lung
parenchyma
indic
distinguish
infect
interstiti
inflammatori
lung
diseas
introduct
highresolut
video
equip
chang
elect
thorac
surgeri
small
incis
thoracoscop
video
camera
fig
surgeon
directli
biopsi
affect
lung
tissu
larg
quantiti
parenchyma
avail
microbiolog
patholog
evalu
fig
videoassist
thorac
surgeri
becom
standard
approach
surgic
biopsi
mortal
low
length
hospit
stay
recoveri
improv
standard
thoracotomi
thorac
access
port
use
ipsilater
lymph
node
may
contain
diseas
abnorm
biopsi
simultan
wedg
lung
biopsi
perform
consult
among
radiologist
chest
physician
thorac
surgeon
essenti
identifi
ideal
locat
biopsi
pneumonia
may
classifi
accord
sever
paramet
includ
pathogenesi
epidemiolog
anatom
pattern
see
fig
clinic
cours
organ
articl
pulmonari
bacteri
infect
divid
cap
health
careassoci
pneumonia
hcap
hospitalacquir
pneumonia
hap
vap
mycobacteri
fungal
viral
infect
also
address
entiti
requir
special
diagnost
treatment
consider
patholog
pattern
agent
common
pulmonari
infect
list
tabl
cap
defin
pneumonia
acquir
outpati
set
patient
common
lower
respiratori
pathogen
suspect
although
virus
fig
endem
fungi
may
caus
cap
definit
treatment
regimen
presuppos
bacteri
origin
common
origin
list
tabl
fig
b
coverag
agent
form
basi
initi
empir
treatment
cap
howev
clinician
must
awar
factor
predispos
patient
pneumonia
caus
drugresist
bacteria
methicillinresist
staphylococcu
aureu
mrsa
pseudomona
aeruginosa
antibiot
select
patient
take
consider
addit
breadth
spectrum
box
american
thorac
societi
infecti
diseas
societi
america
publish
joint
guidelin
diagnosi
manag
cap
box
summar
recommend
empir
antibiot
cap
recommend
treatment
regimen
vari
base
sever
ill
set
eg
outpati
inpati
intens
care
empir
inpati
therapi
strong
evid
support
use
either
respiratori
fluoroquinolon
combin
blactam
plu
macrolid
patient
requir
intens
care
guidelin
recommend
blactam
plu
fluoroquinolon
howev
critic
ill
popul
margin
error
low
mani
clinician
favor
initi
broadspectrum
regimen
includ
antimrsa
antipseudomon
coverag
etiolog
agent
identifi
antimicrobi
therapi
narrow
target
pathogen
tabl
guidelin
recommend
discontinu
therapi
minimum
day
treatment
occur
patient
achiev
clinic
stabil
evidenc
absenc
fever
greater
hour
hypoxia
tachypnea
tachycardia
hypotens
patient
safe
switch
intraven
oral
therapi
hemodynam
stabl
abl
absorb
oral
medic
longer
durat
therapi
may
necessari
patient
experi
improv
identifi
pathogen
sensit
initi
empir
therapi
extrapulmonari
infect
present
subset
patient
present
pneumonia
acquir
commun
risk
factor
diseas
caus
drugresist
pathogen
drp
guidelin
american
thorac
societi
infecti
diseas
societi
america
atsidsa
hap
vap
addit
categori
hcap
propos
exist
paradigm
patient
share
risk
factor
drp
suscept
hap
vap
includ
exposur
p
aeruginosa
extend
spectrum
blactamas
produc
escherichia
coli
klebsiella
acinetobact
burkholderia
drugresist
enterobacteriacea
mrsa
includ
new
classif
patient
hospit
within
past
day
receiv
chemotherapi
wound
care
intraven
antibiot
resid
nurs
home
longterm
facil
patient
undergo
hemodialysi
patient
guidelin
recommend
aggress
empir
antibiot
regimen
includ
antipseudomon
blactam
plu
either
aminoglycosid
tabl
nosocomi
pneumonia
gener
subdivid
hap
includ
postop
pneumonia
vap
hap
defin
pneumonia
occur
patient
hospit
longer
hour
onset
associ
high
mortal
rate
treatment
algorithm
hap
base
individu
risk
drp
see
box
time
onset
patient
preexist
risk
factor
drp
earli
hap
develop
within
first
four
hospit
day
may
treat
blactam
thirdgener
cephalosporin
ampicillinsulbactam
ertapenem
respiratori
fluoroquinolon
levofloxacin
patient
lateonset
hap
five
inpati
day
risk
factor
drp
treat
broadspectrum
regimen
see
tabl
vap
vap
defin
pneumonia
occur
hour
initi
endotrach
intub
mechan
ventil
prior
hospit
within
past
day
prior
antibiot
therapi
predispos
colon
infect
antibioticresist
pathogen
suspect
case
vap
review
risk
factor
sign
antibiot
multidrug
resist
mdr
fig
vap
frequent
acquir
infect
intens
care
unit
icu
incid
gener
vap
preval
surgic
icu
medic
icu
risk
factor
vap
includ
host
intervent
factor
tabl
microb
commonli
associ
vap
similar
caus
hap
tabl
vap
caus
one
pathogen
identifi
case
treatment
initi
empir
therapi
guid
risk
mdr
pathogen
describ
earlier
hcap
hap
tabl
strategi
deescal
empir
broadspectrum
multidrug
regimen
target
therapi
narrow
spectrum
recommend
reduc
antibiot
use
select
pressur
mdr
bacteria
aerosol
antibiot
therapi
icu
grow
bodi
data
suggest
aerosol
antibiot
may
role
treatment
pulmonari
infect
mechan
ventil
patient
tabl
proper
deliveri
antimicrobi
therapi
may
target
directli
site
infect
increas
concentr
lung
minim
system
toxic
tabl
deliveri
mechan
rang
atom
jet
ultrason
nebul
vibrat
mesh
technolog
given
rise
incid
drp
icu
larg
multicent
trial
need
valid
novel
treatment
option
current
guidelin
american
thorac
societi
recommend
routin
use
aerosol
antibiot
therapi
state
aerosol
antibiot
may
consid
treatment
microorgan
high
minimum
inhibitori
concentr
parenter
antibiot
mycobacteri
infect
may
manifest
clinic
vast
variat
pulmonari
infect
common
may
diagnost
challeng
signific
overlap
present
symptom
pulmonari
infect
therefor
diagnosi
often
delay
confirm
invas
procedur
transbronchi
biopsi
transthorac
needl
biopsi
surgic
lung
biopsi
direct
acidfast
bacillu
smear
respiratori
specimen
neg
approxim
case
biopsi
may
first
suggest
mycobacteri
infect
fig
mycobacteri
speci
categor
two
clinic
relev
group
mycobacterium
tuberculosi
complex
nontubercul
mycobacteria
ntm
tuberculosi
virul
mycobacteri
speci
etiolog
agent
tabl
mdr
pathogen
pseudomona
aeruginosa
klebsiella
pneumonia
b
acinetobact
spp
b
antipseudomon
cephalosporin
cefepim
ceftazidim
antipseudomon
carbapenem
imipenem
meropenem
blactamblactamas
inhibitor
piperacillintazobactam
plu
antipseudomon
fluoroquinolon
b
ciprofloxacin
levofloxacin
aminoglycosid
amikacin
gentamicin
tobramycin
plu
linezolid
vancomycin
c
abbrevi
esbl
extendedspectrum
blactamas
initi
antibiot
therapi
adjust
streamlin
base
microbiolog
data
clinic
respons
therapi
b
esbl
strain
k
pneumonia
acinetobact
sp
suspect
carbapenem
reliabl
choic
l
pneumophila
suspect
combin
antibiot
regimen
includ
macrolid
eg
azithromycin
fluoroquinolon
eg
ciprofloxacin
levofloxacin
use
rather
aminoglycosid
c
mrsa
risk
factor
present
high
incid
local
tuberculosi
worldwid
variou
form
organ
respons
death
worldwid
singl
microb
postprimari
tuberculosi
common
form
adult
typic
involv
apic
upper
lobe
produc
granulomat
lesion
caviti
variabl
degre
fibrosi
retract
parenchyma
minor
patient
lesion
enlarg
progress
secondari
increas
necrosi
andor
liquefact
ntm
includ
speci
howev
rel
caus
pulmonari
diseas
ntm
speci
subdivid
accord
growth
rate
rapid
grower
abscessu
frequent
recov
pulmonari
pathogen
wherea
fortuitum
chelona
often
associ
wound
infect
soft
tissu
diseas
among
slow
grower
aviumintracellular
complex
common
ntm
respiratori
pathogen
follow
kansasii
unit
state
xenopi
europ
ntm
may
caus
wide
spectrum
pulmonari
extrapulmonari
diseas
frequent
caus
fibronodular
bronchiectasi
cavit
treatment
mycobacteri
diseas
gener
complic
bacteria
slow
growth
organ
mechan
drug
resist
eg
uniqu
cell
wall
characterist
genu
poor
drug
toler
multidrug
regimen
requir
extend
durat
diagnosi
activ
pulmonari
tuberculosi
confirm
initi
recommend
treatment
compris
fourdrug
regimen
isoniazid
rifampin
pyrazinamid
either
ethambutol
streptomycin
accord
local
pattern
suscept
durat
therapi
depend
drug
suscept
isol
presenc
extrapulmonari
involv
immun
statu
patient
although
acquir
resist
occur
common
caus
treatment
failur
medic
nonadher
reason
evid
strongli
support
direct
observ
therapi
confirm
clearanc
sputum
acidfast
bacilli
recommend
month
given
increas
mdr
extens
drugresist
tuberculosi
strain
repeat
suscept
test
warrant
document
treatment
failur
drugresist
strain
identifi
expert
consult
recommend
regimen
compos
least
four
agent
select
stepwis
approach
follow
class
firstlin
agent
strain
sensit
isoniazid
rifampin
pyrazinamid
ethambutol
one
fluoroquinolon
suscept
one
inject
aminoglycosid
streptomycin
kanamycin
less
effect
secondlin
antitubercul
drug
ethionamid
cycloserin
secondlin
agent
data
avail
linezolid
clarithromycin
amoxicillinclavulan
clofazamin
treatment
pulmonari
ntm
less
well
defin
although
principl
manag
similar
tuberculosi
antibiot
regimen
vari
speci
avium
complex
atsidsa
guidelin
recommend
combin
clarithromycin
rifampicin
ethambutol
wherea
kansasii
initi
regimen
compris
isoniazid
rifampicin
ethambutol
local
pulmonari
abscessu
infect
medic
manag
alon
effect
surgic
resect
requir
tuberculosi
remain
common
caus
hemoptysi
worldwid
howev
unit
state
invas
fungal
infect
chronic
granulomat
diseas
bronchiectasi
bronchiti
account
case
conserv
manag
often
control
bleed
current
recommend
strategi
hemoptysi
initi
nonop
manag
stabil
surgeri
reserv
isol
case
patient
present
massiv
hemoptysi
immedi
goal
surgeon
preserv
life
protect
healthi
lung
aspir
stabil
patient
hemodynam
correct
coagulopathi
bronchoscopi
often
effect
bleed
mild
patient
treat
success
bronchoscop
local
bleed
site
control
balloon
tamponad
laser
ablat
local
vasopressor
therapi
decis
interven
angiograph
made
base
clinic
examin
imag
result
bronchoscop
find
physician
expertis
transcathet
arteri
embol
success
patient
although
bronchial
embol
mainstay
treatment
emerg
surgeri
consid
initi
attempt
control
bleed
stabil
patient
prove
unsuccess
decis
take
patient
oper
room
requir
minimum
known
later
lesion
optim
lobar
locat
fig
rapid
increas
bone
marrow
solid
organ
transplant
invas
fungal
infect
becom
signific
caus
morbid
mortal
although
nearli
fungi
recov
respiratori
infect
small
number
consist
implic
pathogen
box
broadli
fungal
pathogen
infect
lung
includ
yeast
candida
spp
cryptococcu
endem
dimorph
fungi
histoplasma
coccidioid
filament
mold
aspergillu
common
member
famili
mucoral
effect
method
diagnosi
often
identif
fungi
tissu
section
cytolog
sampl
fig
patient
may
present
wide
spectrum
radiograph
pulmonari
diseas
healthi
host
fungal
pathogen
typic
produc
one
nodular
lesion
fig
turn
may
becom
cavitari
lesion
evolv
fig
howev
clinic
present
may
vari
wide
may
includ
solitari
multipl
bilater
nodular
lesion
segment
lobar
consolid
cavitari
lesion
fistula
infarct
direct
extens
mediastin
thorac
soft
tissu
chest
wall
diaphragm
chronic
tracheal
endobronchi
infect
fungu
ball
aspergilloma
proxim
endobronchi
diseas
mimick
neoplasm
also
describ
variou
fungal
speci
recent
effect
treatment
option
invas
fungal
infect
larg
limit
amphotericin
b
deoxychol
well
known
potenti
system
toxic
howev
develop
lipid
liposom
aerosol
formul
amphotericin
b
newer
triazol
echinocandin
antifung
agent
greatli
expand
treatment
option
diseas
differ
antifung
suscept
prognosi
dimorph
endem
fungi
filament
fungi
mold
eg
mucor
definit
microbiolog
patholog
diagnosi
strongli
prefer
treatment
invas
aspergillu
infect
larg
random
control
trial
show
superior
voriconazol
amphotericin
b
treatment
invas
pulmonari
aspergillosi
patient
limit
data
suggest
certain
popul
heart
transplant
recipi
voriconazol
combin
therapi
caspofungin
may
contribut
improv
outcom
addit
data
anticip
lung
transplant
recipi
aerosol
amphotericin
b
use
antifung
prophylaxi
adjunct
therapi
invas
fungal
diseas
pulmonari
mucormycosi
howev
voriconazol
ineffect
prefer
treatment
remain
amphotericin
b
although
data
suggest
liposom
amphotericin
b
may
efficaci
deoxychol
formul
novel
triazol
posaconazol
also
approv
salvag
therapi
limit
avail
oral
formul
inconsist
bioavail
limit
evid
also
suggest
improv
outcom
combin
therapi
amphotericin
b
posaconazol
echinocandin
empir
therapi
requir
critic
ill
patient
hemodynam
instabl
cytopenia
may
prevent
invas
diagnost
procedur
logic
approach
combin
therapi
voriconazol
amphotericin
b
virus
caus
infect
respiratori
tract
type
microorgan
combin
virus
commonli
infect
lung
present
box
common
respiratori
virus
eg
influenza
parainfluenza
respiratori
syncyti
viru
adenoviru
caus
outbreak
respiratori
ill
gener
popul
year
fortun
viral
respiratori
infect
mild
selflimit
howev
virus
also
capabl
produc
seriou
lifethreaten
infect
case
primari
varicellazost
pneumonia
respiratori
diseas
caus
highli
pathogen
strain
influenza
addit
viralmedi
bronchial
epitheli
damag
predispos
suscept
patient
secondari
bacteri
infect
associ
signific
morbid
mortal
recent
outbreak
strain
influenza
serv
highlight
increas
risk
mortal
associ
influenza
complic
secondari
bacteri
infect
especi
aureu
immunocompromis
host
less
common
viral
agent
may
caus
sever
clinic
diseas
patient
diagnosi
may
made
respiratori
cytolog
specimen
herp
simplex
cytomegaloviru
adenoviru
commonli
identifi
viral
pathogen
cytolog
featur
viral
infect
respiratori
tract
like
found
exfoli
specimen
bronchial
wash
bronchoalveolar
lavag
treatment
viral
pulmonari
infect
respiratori
infect
caus
virus
treatment
necessari
consensu
exist
prophylact
antibiot
treatment
influenzalik
ill
howev
secondari
bacteri
pneumonia
suspect
antibacteri
agent
target
common
caus
pathogen
pneumonia
aureu
includ
mrsa
initi
treatment
option
primari
viral
respiratori
tract
infect
limit
influenza
earli
treatment
oseltamivir
zanamivir
within
hour
onset
symptom
shown
decreas
complic
especi
young
elderli
individu
patient
impair
immun
statu
comorbid
condit
tabl
summar
possibl
antivir
treatment
prevent
sever
viral
pneumonia
